Notice: Eric Fry Will Reveal His “Nvidia on Steroids” Pick on Wednesday, Sept. 10

Eric Fry has shown his followers more than 40 gains of 1,000% or more already. Now he says a little-known AI robotics stock could be the “Next Nvidia on Steroids.” His new Apogee system flagged it using the same 10X Pattern that appeared before Nvidia’s 1,871% run… Apple’s 4,285% surge… and Amazon’s 1,115% climb during the system’s 5.2 million back-tests. Eric will reveal full details down to the ticker, for free, on Sept. 10.

Wed, September 10 at 10:00AM ET

Days

Hours

Minutes

Seconds

Legendary Stock Picker Eric Fry Reveals 7 Stocks to Buy and Hold Forever in 2025

OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023

OncoCyte just reported results for the fourth quarter of 2023

By InvestorPlace Earnings Apr 12, 2024, 10:52 am EDT September 19, 2024

OCX stock - OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 — Source: iQoncept / Shutterstock

OncoCyte (NASDAQ:OCX) just reported results for the fourth quarter of 2023.

OncoCyte reported earnings per share of -$2.18. This was below the analyst estimate for EPS of -$1.14.
The company reported revenue of $314,000.
This was 1.88% worse than the analyst estimate for revenue of $320,000.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/04/ocx-stock-earnings-oncocyte-for-q4-of-2023/.

Subscriber Sign in